These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17127735)

  • 1. Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer.
    Kim M; Park IY; Lim J; Kim Y; Han KT; Chung WH; Han K
    Ann Clin Lab Sci; 2006; 36(4):455-60. PubMed ID: 17127735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
    Zaugg K; Rocha S; Resch H; Hegyi I; Oehler C; Glanzmann C; Fabbro D; Bodis S; Pruschy M
    Cancer Res; 2001 Jan; 61(2):732-8. PubMed ID: 11212276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
    Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
    Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
    El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H
    Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
    Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
    Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PKC412--a protein kinase inhibitor with a broad therapeutic potential.
    Fabbro D; Ruetz S; Bodis S; Pruschy M; Csermak K; Man A; Campochiaro P; Wood J; O'Reilly T; Meyer T
    Anticancer Drug Des; 2000 Feb; 15(1):17-28. PubMed ID: 10888033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
    Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of PKC412, an inhibitor of protein kinase C, on spontaneous metastatic model mice.
    Nakamura K; Yoshikawa N; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
    Anticancer Res; 2003; 23(2B):1395-9. PubMed ID: 12820400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on murine and human tumor models.
    Ikegami Y; Yano S; Nakao K; Fujita F; Fujita M; Sakamoto Y; Murata N; Isowa K
    Arzneimittelforschung; 1995 Nov; 45(11):1225-30. PubMed ID: 8929245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
    Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
    Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
    Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
    Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
    Yang X; Shen J; Gao Y; Feng Y; Guan Y; Zhang Z; Mankin H; Hornicek FJ; Duan Z
    Int J Cancer; 2015 Oct; 137(8):2029-39. PubMed ID: 25904021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
    Tong L; Chen W; Wu J; Li H
    Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
    Lengyel E; Litchfield LM; Mitra AK; Nieman KM; Mukherjee A; Zhang Y; Johnson A; Bradaric M; Lee W; Romero IL
    Am J Obstet Gynecol; 2015 Apr; 212(4):479.e1-479.e10. PubMed ID: 25446664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice.
    Hou WJ; Guan JH; Dong Q; Han YH; Zhang R
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2902-8. PubMed ID: 24254559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells.
    Li JP; Huang ZJ; Lu XS; Zhou YC; Shao Y; He XP; Chen SR; Wang DD; Qin LS; Sun WH
    Oncotarget; 2016 Nov; 7(47):77815-77824. PubMed ID: 27780925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
    Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enhancement of antitumor effect of cisplatin on human ovarian cancer by cyclosporin A in vitro and in vivo].
    Zhou Y; Chen H; Yang Q
    Zhonghua Fu Chan Ke Za Zhi; 1996 Jan; 31(1):25-8. PubMed ID: 8758815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
    Cooper AL; Greenberg VL; Lancaster PS; van Nagell JR; Zimmer SG; Modesitt SC
    Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.